Asia-Pacific’s medical devices industry saw a drop of 25.58% in deal activity during April 2022, when compared with the last 12-month average, led by Winner Medical Group’s $114.35m acquisition of 55% stake in Zhejiang Longtai Medical Technology, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 32 medical devices industry deals worth $382m were announced for the region in April 2022, against the 12-month average of 43 deals.
Of all the deal types, venture financing saw most activity in April 2022 with 28 transactions, representing an 87.5% share for the region.
In second place was M&A with four deals capturing a 12.5% share of the overall deal activity for the month.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn terms of value of deals, M&A was the leading category in Asia-Pacific’s medical devices industry with $193.19m, followed by venture financing deals totalled $188.77m.
Asia-Pacific medical devices industry deals in April 2022: Top deals
The top five medical devices deals accounted for 76.02% of the overall value during April 2022.
The combined value of the top five medical devices deals stood at $290.35m, against the overall value of $382m recorded for the month.
The top five medical devices industry deals of April 2022 tracked by GlobalData were:
1) Winner Medical Group $114.35m acquisition deal for 55% stake in Zhejiang Longtai Medical Technology
2) The $74.59m acquisition of ResApp Health by Pfizer Australia Holdings
3) Globis Capital Partners &,Incubate Fund,SoftBank Vision Fund 2 and World Innovation Lab (WiL fund) $70m venture financing deal with AI Medical Service
4) The $15.71m venture financing of Shanghai Yipu Biotechnology by Industrial Capital
5) Boyuan Capital,Guotai Junan Innovation Investment and Yinshengtai Capital $15.7m venture financing deal with Shanghai Ruijing Biotechnology
